Reports for APOTEX INC
Company Name
APOTEX INC
Totals |
||
Shortage reports |
3356 |
|
| Actual shortage: | 218 (6%) | |
| Anticipated shortage: | 0 (0%) | |
| Avoided shortage: | 10 (0%) | |
| Resolved: | 3128 (93%) | |
Discontinuation Reports |
359 |
|
| To be discontinued: | 24 (7%) | |
| Discontinued: | 335 (93%) | |
| Reversed: | 0 (0%) | |
Late reports |
144 (4%) |
|
Overdue reports |
61 (25%) |
|
Shortage reports
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-SERTRALINE | 50MG | CAPSULE | Resolved | 2024-08-09 | 2024-09-06 | 234992 |
| APO-SERTRALINE | 50MG | CAPSULE | Resolved | 2022-12-09 | 2022-12-23 | 177597 |
| APO-SERTRALINE | 50MG | CAPSULE | Resolved | 2021-03-05 | 2021-03-15 | 135174 |
| APO-SERTRALINE | 100MG | CAPSULE | Resolved | 2018-05-08 | 2018-05-29 | 48860 |
| APO-SERTRALINE | 25MG | CAPSULE | Resolved | 2018-05-15 | 2018-06-12 | 49374 |
| APO-SERTRALINE | 25MG | CAPSULE | Resolved | 2018-07-16 | 2018-08-31 | 55847 |
| APO-SERTRALINE | 100MG | CAPSULE | Resolved | 2018-08-09 | 2018-11-27 | 57820 |
| APO-SERTRALINE | 50MG | CAPSULE | Resolved | 2023-02-16 | 2023-03-23 | 185004 |
| APO-SERTRALINE | 100MG | CAPSULE | Resolved | 2017-09-04 | 2017-10-05 | 20903 |
| APO-SERTRALINE | 100MG | CAPSULE | Resolved | 2017-11-09 | 2018-01-31 | 28709 |
| APO-SERTRALINE | 25MG | CAPSULE | Resolved | 2017-11-28 | 2018-02-23 | 30963 |
| APO-SERTRALINE | 50MG | CAPSULE | Resolved | 2017-11-28 | 2018-01-18 | 30967 |
| APO-SERTRALINE | 50MG | CAPSULE | Resolved | 2018-02-21 | 2018-06-12 | 40377 |
| APO-SILDENAFIL | 100MG | TABLET | Resolved | 2017-11-09 | 2018-01-03 | 28700 |
| APO-SILDENAFIL | 25MG | TABLET | Resolved | 2021-06-04 | 2021-07-19 | 140431 |
| APO-SILDENAFIL | 50MG | TABLET | Resolved | 2021-06-04 | 2021-08-23 | 140434 |
| APO-SILDENAFIL | 100MG | TABLET | Resolved | 2021-12-10 | 2021-12-22 | 150899 |
| APO-SILDENAFIL | 50MG | TABLET | Resolved | 2021-12-10 | 2021-12-22 | 150910 |
| APO-SILDENAFIL | 50MG | TABLET | Resolved | 2023-07-27 | 2023-08-12 | 200188 |
| APO-SILDENAFIL | 50MG | TABLET | Resolved | 2023-10-27 | 2023-12-01 | 208414 |
Discontinuation reports
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-BISACODYL | 5MG | TABLET (DELAYED-RELEASE) | Discontinued | 2018-09-07 | 2018-09-15 | 60288 |
| APO-BOSENTAN | 62.5MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71339 |
| APO-BOSENTAN | 125.0MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71342 |
| APO-BOSENTAN | 125.0MG | TABLET | Discontinued | 2018-09-07 | 2018-10-31 | 60291 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | Discontinued | 2020-11-16 | 2020-11-16 | 128438 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | To be discontinued | 2018-09-07 | 2018-09-07 | 60294 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | Discontinued | 2018-09-07 | 2018-12-28 | 60301 |
| APO-BROMAZEPAM | 1.5MG | TABLET | To be discontinued | 2018-09-07 | 2018-09-07 | 60304 |
| APO-BROMAZEPAM | 3MG | TABLET | Discontinued | 2018-09-07 | 2019-06-12 | 60307 |
| APO-BROMAZEPAM | 6MG | TABLET | Discontinued | 2018-09-07 | 2018-10-19 | 60310 |
| APO-CANDESARTAN | 16MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60313 |
| APO-CANDESARTAN | 16MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60316 |
| APO-CANDESARTAN | 32MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60328 |
| APO-CANDESARTAN | 8MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60325 |
| APO-CANDESARTAN | 8MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60322 |
| APO-CANDESARTAN | 4MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60319 |
| APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60335 |
| APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60331 |
| APO-CANDESARTAN/HCTZ | 25MG 32MG | TABLET | Discontinued | 2018-02-26 | 2018-05-03 | 41011 |
| APO-CANDESARTAN/HCTZ | 12.5MG 32MG | TABLET | Discontinued | 2018-02-26 | 2018-02-26 | 41020 |